Saeid Amiri Zadeh Fard, Haniyeh Abuei, Abbas Behzad Behbahani, Gholamreza Rafiei dehbidi, F. Zare, Maryam Nejabat, Alireza Safarpour, Ali Farhadi
{"title":"释放治疗潜力:在人类呼吸道合胞病毒治疗中利用 Tat 肽增强 shRNA 递送","authors":"Saeid Amiri Zadeh Fard, Haniyeh Abuei, Abbas Behzad Behbahani, Gholamreza Rafiei dehbidi, F. Zare, Maryam Nejabat, Alireza Safarpour, Ali Farhadi","doi":"10.34172/apb.2024.045","DOIUrl":null,"url":null,"abstract":"Purpose: This research investigated the development of short hairpin RNA (shRNA) molecules designed to target specific regions of the HRSV M and F genes. The study aimed to assess the therapeutic potential of these shRNAs and evaluate the effectiveness of Tat peptide-mediated delivery in enhancing their functionality. Methods: To investigate the therapeutic potential of short hairpin RNA against HRSV, we acquired isolates from pediatric patients experiencing respiratory illness. These isolates were then cultured in human epidermoid carcinoma cells (HEp-2). To target the M and F genes of HRSV, we constructed plasmids expressing shRNAs. We further investigated the Tat peptide as a facilitator for shRNA plasmid delivery. The cytotoxicity of ribavirin, shRNA constructs, and control agents was assessed using the MTT assay. Next, we compared the transfection efficiency of Tat peptide-mediated shRNA delivery with that of lipofectamine 3000™. Finally, real-time PCR was employed to quantify HRSV replication in the treated cells. Results: Our study successfully demonstrated that Tat peptide-mediated delivery of shRNA plasmids significantly suppressed the expression of the M and F genes of HRSV compared to lipofectamine 3000™. This suppression was evident in both short-term experiments and scenarios involving stable shRNA expression. Furthermore, the combination of ribavirin with shRNA treatment resulted in a substantial reduction in viral load. Notably, the most pronounced antiviral effect was observed when both shRNAs were employed simultaneously. Conclusion: Our findings suggest that Tat peptide-mediated delivery of shRNA plasmids holds significant potential for achieving stable suppression of HRSV genes. This approach warrants further investigation as a potential gene therapy strategy for HRSV. By demonstrating promising results in vitro, this study highlights the need for future in vivo studies to comprehensively evaluate the therapeutic potential of this approach in a clinical setting.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unlocking Therapeutic Potential: Enhanced shRNA delivery with Tat peptide in the Human Respiratory Syncytial Virus Treatment\",\"authors\":\"Saeid Amiri Zadeh Fard, Haniyeh Abuei, Abbas Behzad Behbahani, Gholamreza Rafiei dehbidi, F. Zare, Maryam Nejabat, Alireza Safarpour, Ali Farhadi\",\"doi\":\"10.34172/apb.2024.045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: This research investigated the development of short hairpin RNA (shRNA) molecules designed to target specific regions of the HRSV M and F genes. The study aimed to assess the therapeutic potential of these shRNAs and evaluate the effectiveness of Tat peptide-mediated delivery in enhancing their functionality. Methods: To investigate the therapeutic potential of short hairpin RNA against HRSV, we acquired isolates from pediatric patients experiencing respiratory illness. These isolates were then cultured in human epidermoid carcinoma cells (HEp-2). To target the M and F genes of HRSV, we constructed plasmids expressing shRNAs. We further investigated the Tat peptide as a facilitator for shRNA plasmid delivery. The cytotoxicity of ribavirin, shRNA constructs, and control agents was assessed using the MTT assay. Next, we compared the transfection efficiency of Tat peptide-mediated shRNA delivery with that of lipofectamine 3000™. Finally, real-time PCR was employed to quantify HRSV replication in the treated cells. Results: Our study successfully demonstrated that Tat peptide-mediated delivery of shRNA plasmids significantly suppressed the expression of the M and F genes of HRSV compared to lipofectamine 3000™. This suppression was evident in both short-term experiments and scenarios involving stable shRNA expression. Furthermore, the combination of ribavirin with shRNA treatment resulted in a substantial reduction in viral load. Notably, the most pronounced antiviral effect was observed when both shRNAs were employed simultaneously. Conclusion: Our findings suggest that Tat peptide-mediated delivery of shRNA plasmids holds significant potential for achieving stable suppression of HRSV genes. This approach warrants further investigation as a potential gene therapy strategy for HRSV. By demonstrating promising results in vitro, this study highlights the need for future in vivo studies to comprehensively evaluate the therapeutic potential of this approach in a clinical setting.\",\"PeriodicalId\":7256,\"journal\":{\"name\":\"Advanced pharmaceutical bulletin\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-05-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advanced pharmaceutical bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/apb.2024.045\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced pharmaceutical bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/apb.2024.045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究调查了针对 HRSV M 和 F 基因特定区域设计的短发夹 RNA (shRNA) 分子的开发情况。研究旨在评估这些 shRNA 的治疗潜力,并评价 Tat 肽介导的递送在增强其功能方面的有效性。研究方法为了研究短发夹 RNA 对 HRSV 的治疗潜力,我们从患有呼吸道疾病的儿科患者身上获得了分离物。然后将这些分离株培养在人类表皮癌细胞(HEp-2)中。为了靶向 HRSV 的 M 和 F 基因,我们构建了表达 shRNA 的质粒。我们进一步研究了作为 shRNA 质粒递送促进剂的 Tat 肽。我们使用 MTT 试验评估了利巴韦林、shRNA 构建体和对照药剂的细胞毒性。接着,我们比较了 Tat 肽介导的 shRNA 转染效率和脂质体转染胺 3000™ 的转染效率。最后,我们使用实时 PCR 对处理过的细胞中的 HRSV 复制进行了量化。结果我们的研究成功证明,与脂质体转染胺 3000™ 相比,Tat 肽介导的 shRNA 质粒能显著抑制 HRSV M 和 F 基因的表达。这种抑制作用在短期实验和涉及 shRNA 稳定表达的情况下都很明显。此外,利巴韦林与 shRNA 联合治疗可大幅降低病毒载量。值得注意的是,当两种 shRNA 同时使用时,抗病毒效果最为明显。结论我们的研究结果表明,Tat 肽介导的 shRNA 质粒在稳定抑制 HRSV 基因方面具有巨大潜力。作为一种潜在的 HRSV 基因治疗策略,这种方法值得进一步研究。本研究通过在体外展示有前景的结果,强调了未来进行体内研究的必要性,以全面评估这种方法在临床环境中的治疗潜力。
Unlocking Therapeutic Potential: Enhanced shRNA delivery with Tat peptide in the Human Respiratory Syncytial Virus Treatment
Purpose: This research investigated the development of short hairpin RNA (shRNA) molecules designed to target specific regions of the HRSV M and F genes. The study aimed to assess the therapeutic potential of these shRNAs and evaluate the effectiveness of Tat peptide-mediated delivery in enhancing their functionality. Methods: To investigate the therapeutic potential of short hairpin RNA against HRSV, we acquired isolates from pediatric patients experiencing respiratory illness. These isolates were then cultured in human epidermoid carcinoma cells (HEp-2). To target the M and F genes of HRSV, we constructed plasmids expressing shRNAs. We further investigated the Tat peptide as a facilitator for shRNA plasmid delivery. The cytotoxicity of ribavirin, shRNA constructs, and control agents was assessed using the MTT assay. Next, we compared the transfection efficiency of Tat peptide-mediated shRNA delivery with that of lipofectamine 3000™. Finally, real-time PCR was employed to quantify HRSV replication in the treated cells. Results: Our study successfully demonstrated that Tat peptide-mediated delivery of shRNA plasmids significantly suppressed the expression of the M and F genes of HRSV compared to lipofectamine 3000™. This suppression was evident in both short-term experiments and scenarios involving stable shRNA expression. Furthermore, the combination of ribavirin with shRNA treatment resulted in a substantial reduction in viral load. Notably, the most pronounced antiviral effect was observed when both shRNAs were employed simultaneously. Conclusion: Our findings suggest that Tat peptide-mediated delivery of shRNA plasmids holds significant potential for achieving stable suppression of HRSV genes. This approach warrants further investigation as a potential gene therapy strategy for HRSV. By demonstrating promising results in vitro, this study highlights the need for future in vivo studies to comprehensively evaluate the therapeutic potential of this approach in a clinical setting.